Table 1.
Patient lesion categories for the 1,305-patient prospective cohort and 22-patient retrospective cohort
| Lesion categories | Description | Total study (n = 1,327) | Prospective training set (n = 939) | Prospective testing set (n = 366) | Retrospective testing set (n = 22) |
| CRC (1.0) | Stage I–IV CRC | 25 (1.7%) | 3 (0.3%) | 2 (0.6%) | 20 (91.0%) |
| AA (2.1) | >10 adenomas (TA + SSA + VA + TVA); adenoma with high-grade dysplasia; adenoma with carcinoma in situ | 7 (0.5%) | 3 (0.3%) | 3 (0.8%) | 1 (4.5%) |
| AA (2.2) | Villous adenoma; tubulovillous adenoma | 39 (2.9%) | 23 (2.5%) | 15 (4.1%) | 1 (4.5%) |
| AA (2.3) | Tubular adenoma ≧ 10 mm; 5–10 adenomas (TA only) | 50 (3.8%) | 28 (3.0%) | 22 (6.0%) | 0 (0.0%) |
| AA (2.4) | SSA ≧ 10 mm; 5–10 adenomas (TA + SSA) | 22 (1.7%) | 12 (1.3%) | 10 (2.7%) | 0 (0.0%) |
| ONA (3.0) | 1–2 adenomas (TA + SSA) between 5 and 10 mm; >20 hyperplastic polyps | 123 (9.3%) | 81 (8.6%) | 42 (11.5%) | 0 (0.0%) |
| ONA (4.0) | 3–4 adenomas (TA + SSA) < 10 mm | 62 (4.7%) | 35 (3.7%) | 27 (7.4%) | 0 (0.0%) |
| ONA (5.0) | 1–2 adenomas (TA + SSA) ≦5 mm | 233 (17.6%) | 163 (17.4%) | 70 (19.1%) | 0 (0.0%) |
| Hyperplastic polyp (6.1) | ≦20 hyperplastic polyps | 229 (17.3%) | 155 (16.5%) | 74 (20.2%) | 0 (0.0%) |
| No findings (6.2) | No findings on colonoscopy; No histopathological abnormalities | 537 (40.5%) | 436 (46.4%) | 101 (27.6%) | 0 (0.0%) |
| Total | 1,327 | 939 | 366 | 22 |
This table enumerates lesion categories for the total study, the prospective training set, the prospective testing set, and the retrospective testing set.
AA, advanced adenoma; CRC, colorectal cancer; ONA, other non-AA; SSA, sessile serrated adenoma/sessile serrated polyp; TA, tubular adenoma; TVA, tubulovillous adenoma; VA, villous adenoma.